Actively Recruiting
Phase 2 Study Evaluating ADX-038 Treatment for Adults with Complement-Mediated Kidney Diseases Including IgA Nephropathy and C3 Glomerulopathy
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-07-27
45
Participants Needed
34
Research Sites
21 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating ADX-038, an investigational siRNA duplex oligonucleotide drug, in adults with complement-mediated kidney diseases such as IgA nephropathy IgAN, C3 glomerulopathy C3G, and immune complex-mediated membranoproliferative glomerulonephritis IC-MPGN. This Phase 2 study aims to assess the safety, effectiveness, and how the drug behaves in the body pharmacokinetics and pharmacodynamics. Participants will receive one of two dose levels of ADX-038. The study includes groups with different kidney disease types receiving different doses. The treatment is given as part of a parallel, non-randomized study design. Vaccinations may be required as part of the protocol. During the study, participants undergo monitoring for safety and tolerability over a period of up to 36 months. Researchers will evaluate kidney function and disease activity, and participants will be closely observed for any side effects. The study will last until June 2029, with the primary completion expected by the end of 2028.
CONDITIONS
Brief Title
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Research Team
T
Tracy Nguyen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
